Principal Investigators




    Contact information of lead PI



    Title of project or programme

    The Biology of Neuroserpin

    Source of funding information


    Total sum awarded (Euro)

    € 1,459,028.44

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Parkinson's disease & PD-related disorders|Alzheimer's disease & other dementias


    neuroserpin, Plasminogen Activator, platelet-derived growth factor C, neurovascular, Platelet-Derived Growth Factor alpha Receptor

    Research Abstract

    ? DESCRIPTION (provided by applicant): Neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease are devastating conditions affecting more than 6 million Americans in 2012, and according to the Alzheimer’s Association and the Parkinson’s Disease Foundation the incidences of both disorders are expected to more than double by 2050. Neurodegeneration is the progressive loss of neuronal structure and function, and currently there are no effective treatments that halt or slow neurodegenerative diseases. The causes of most neurodegenerative diseases are not known; however, research has suggested that there may be common or overlapping pathways that promote their development. The identification of common pathways that affect the development and progression of neurodegenerative diseases would provide essential insight into these devastating disorders, and importantly offer novel opportunities for therapeutic intervention. One potential common pathway that may impact diverse central nervous system (CNS) disorders is dysregulation of neurovascular responses. Neurovascular responses are primarily controlled by the neurovascular unit (NVU) and recent work suggests that the serine protease tissue-type plasminogen activator (tPA) acting on the NVU may play a critical role in the regulation of neurovascular responses. The primary inhibitor of tPA in the CNS is the serine protease inhibitor (serpin) neuroserpin (Nsp), and data from the previous funding period of this application suggests that like tPA, Nsp can also regulate neurovascular responses. By using a combination of molecular and genetic approaches in vivo, studies will characterize the activities of Nsp and tPA in the CNS, and examine their role(s) in normal and pathologic CNS physiology. Based on our previous studies and the work of others, we will test the hypothesis that tPA in the NVU activates latent PDGF-CC which mediates neurovascular responses that can increase both cerebral blood flow and blood brain barrier (BBB) permeability, and that Nsp, expressed in vasoregulatory interneurons, can be released to moderate the activity of tPA and facilitate the return of the cerebral vessels to baseline levels o blood flow and permeability. Finally, we will test the highly innovative hypothesis that tPA/Nsp-mediated dysregulation of neurovascular responses may be a common feature in the development of neurodegenerative disorders.

    Lay Summary

    PUBLIC HEALTH RELEVANCE: Neurological disorders affect nearly one billion people worldwide; including 50 million who suffer from epilepsy and 10 million with Parkinson’s disease. This application examines how the regulation of blood vessels in the brain affect normal brain function, and the development of disorders of the brain such seizures and Parkinson’s disease. By understanding how incorrectly regulated blood vessel responses contribute to neurological disease, it is expected that new treatments for neurological diseases can be identified.

    Further information available at:

Types: Investments > €500k
Member States: United States of America
Diseases: Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF